Saxenda vs Mounjaro: Which Is Better For Weight Loss?
Quick Answer
Mounjaro generally shows stronger average weight loss outcomes than Saxenda based on clinical trial evidence, largely because it activates two hormone pathways rather than one and is injected weekly rather than daily. However, the right choice depends on your individual medical history, tolerability and prescriber assessment rather than trial averages alone. Both are effective treatments when used correctly and with appropriate clinical support.
Both Saxenda and Mounjaro are prescription injectable treatments for weight loss, but they are not the same medication and they do not work in exactly the same way. Understanding the differences between them, in terms of mechanism, dosing, expected results and side effects, helps patients in Airdrie make more informed decisions alongside their prescriber.
Key points you should know are:
- Saxenda contains liraglutide and is injected daily
- Mounjaro contains tirzepatide and is injected weekly
- Mounjaro uses a dual hormone mechanism while Saxenda uses a single one
- Clinical evidence suggests Mounjaro produces stronger average weight loss outcomes
- Individual suitability depends on medical history, tolerability and prescriber assessment
If you are weighing up your options and would like clinical guidance, contact us or book a consultation with our Airdrie team.
What Is Saxenda?
Saxenda is the brand name for liraglutide 3mg, a GLP-1 receptor agonist that was one of the earlier injectable weight loss treatments to receive regulatory approval in the UK. It works by mimicking GLP-1, a naturally occurring hormone that regulates appetite and slows gastric emptying. Saxenda is administered via a daily subcutaneous injection and follows a dose escalation schedule over several weeks before reaching the maintenance dose of 3mg daily.
Saxenda was developed following the earlier use of liraglutide at a lower dose (1.2mg and 1.8mg) for type 2 diabetes management under the brand name Victoza. The higher dose version for weight loss (Saxenda) received approval based on clinical evidence demonstrating meaningful weight reduction in adults with obesity or weight related conditions.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Unlike Saxenda, which activates a single hormone receptor pathway, Mounjaro activates two distinct pathways simultaneously. This dual mechanism is believed to produce a stronger and more sustained appetite suppressing effect than single GLP-1 agonism alone.
Mounjaro is injected once weekly rather than daily, and follows a dose escalation schedule beginning at 2.5mg and increasing gradually up to 15mg. The weekly dosing schedule is one of the practical differences many patients find significant when comparing the two treatments.
Mechanism Comparison
| Feature | Saxenda (liraglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Active ingredient | Liraglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist (single) | GLP-1 and GIP receptor agonist (dual) |
| Injection frequency | Daily | Weekly |
| Maintenance dose | 3mg daily | Up to 15mg weekly |
| Average weight loss (clinical trials) | Approximately 5 to 8 percent of body weight | Approximately 15 to 22 percent of body weight |
How Do Their Results Compare?
The clinical evidence base for both medications shows that each can support meaningful weight loss, but the magnitude of results differs significantly between them. Mounjaro’s SURMOUNT trial programme demonstrated substantially larger average weight reductions than those seen in Saxenda’s SCALE trial programme.
This difference in outcomes is generally attributed to Mounjaro’s dual hormone mechanism. By activating both GLP-1 and GIP receptors, tirzepatide produces stronger appetite suppression and appears to have additional metabolic effects that go beyond GLP-1 agonism alone. However, clinical trial averages do not predict individual results, and some patients respond very well to Saxenda while others may see more modest results on Mounjaro.
It is also worth noting that Saxenda’s daily injection schedule can be more challenging to maintain consistently over time compared to Mounjaro’s once weekly injection, and adherence is a significant factor in real world outcomes.
Side Effect Comparison
Both medications share a similar side effect profile, largely because both activate GLP-1 receptors. The most commonly reported effects with both include:
- Nausea, particularly during dose increases
- Vomiting
- Constipation or diarrhoea
- Stomach discomfort
- Reduced appetite beyond the intended therapeutic effect
The intensity and pattern of these side effects may differ between the two treatments depending on individual sensitivity. For patients considering Mounjaro specifically, our guide to Mounjaro long term side effects covers what to expect beyond the initial adjustment period. The daily dosing of Saxenda means any dose-related side effects occur more frequently than the once weekly pattern of Mounjaro, which some patients find makes the experience of adjustment more manageable.
Who Might Saxenda Still Be Right For?
While Mounjaro’s clinical evidence is generally stronger, Saxenda may still be appropriate in certain circumstances. These include:
- Patients who have previously responded well to Saxenda and are continuing established treatment
- Patients for whom Mounjaro is contraindicated for clinical reasons
- Situations where access to Mounjaro is not available or practical
- Patients who prefer or require daily dosing for specific reasons
The decision should always be made in consultation with a prescriber who can assess your medical history, previous treatment experience and current health status.
Cost Considerations
Cost is a practical factor in choosing between treatments. Both Saxenda and Mounjaro are available privately in the UK. Saxenda has been available for longer and may in some cases be priced differently from Mounjaro, though pricing varies between providers and can change over time.
It is worth noting that Saxenda’s daily injection frequency means you are using the medication more frequently, which can affect the total monthly cost of treatment alongside any consultation and review fees. Mounjaro’s once weekly schedule means a month’s supply requires fewer doses.
The Evidence Base: What The Trials Tell Us
When comparing Saxenda and Mounjaro on clinical evidence, the trial programmes that supported each medication’s approval are the most relevant reference point. Saxenda’s SCALE trial programme demonstrated meaningful but more modest average weight loss compared to placebo, while Mounjaro’s SURMOUNT trials showed substantially larger average reductions.
It is important to note that these trials used different populations, different primary endpoints and different timeframes, making direct head to head comparison somewhat imprecise. What the combined evidence does suggest is that dual GLP-1 and GIP agonism, as provided by Mounjaro, produces stronger average results than single GLP-1 agonism alone for most patient populations studied. Individual results, however, always vary and trial averages should never be taken as a guaranteed personal outcome.
Why Newer Does Not Always Mean Better For Everyone
It is tempting to assume that the newer medication with the stronger trial results is always the right choice. In practice, clinical decision making involves more nuance. A patient who has already started Saxenda and is responding well has a strong reason to continue with an established, effective treatment rather than switching simply because a newer option exists.
Similarly, a patient with a specific contraindication that applies to Mounjaro but not Saxenda would be appropriately prescribed Saxenda regardless of the comparative trial results. Clinical appropriateness always takes priority over headline comparison figures, which is why a proper prescriber assessment remains the most important step before starting either treatment.
Our Approach To Helping You Choose
At CarePoint Pharmacy in Airdrie, we do not apply a one-size-fits-all approach to prescribing. When a patient is comparing treatment options, our process includes:
- Reviewing your medical history and any previous treatment experience
- Discussing the clinical evidence for each option in the context of your goals
- Assessing any contraindications or factors that favour one medication over the other
- Explaining the practical differences in dosing schedule and what this means day to day
- Making a recommendation based on the full picture, not just the headline trial results
Long Term Weight Maintenance: How Do The Two Compare?
Weight maintenance after stopping either medication is a consideration that applies to both Saxenda and Mounjaro equally. Neither produces permanent changes to the underlying appetite regulation systems, and weight regain after stopping is a known and well-documented pattern for both. The degree of regain depends heavily on the lifestyle habits built during treatment, the duration of treatment and whether any maintenance plan is in place.
One relevant difference is that the stronger appetite suppressing effect of Mounjaro during treatment may give patients more time to build and consolidate better eating habits before stopping, which could support better maintenance outcomes. However, this is an individual consideration and neither medication guarantees weight maintenance after discontinuation without supporting lifestyle habits.
Access And Availability In The UK
Both Saxenda and Mounjaro are available through regulated private prescribers in the UK. Saxenda has been available for longer and the prescribing infrastructure around it is well established. Mounjaro, while more recently approved for weight loss in the UK, has grown rapidly in availability and is now widely accessible through regulated private pharmacies.
Supply chain considerations occasionally affect availability of both medications, and it is worth discussing current stock and lead times with your pharmacy when planning treatment. At CarePoint Pharmacy, we keep patients informed of any supply issues as early as possible to minimise disruption to treatment schedules.
Making The Decision: Questions To Ask At Your Consultation
Choosing between Saxenda and Mounjaro is best approached as a conversation with your prescriber rather than a decision made purely on the basis of general information. Useful questions to raise at your consultation include:
- Which medication is more appropriate given my specific medical history and any contraindications?
- What results might I realistically expect based on the clinical evidence and my individual profile?
- How would each medication’s dosing schedule fit my lifestyle and routine?
- What does the monitoring and support process look like throughout treatment?
- Are there any cost considerations I should be aware of for either option?
These questions help ensure the decision is based on your circumstances rather than on headline comparisons between the two treatments.
What Both Medications Have In Common
Amidst the comparisons, it is worth acknowledging what Saxenda and Mounjaro share. Both are clinically significant treatments for chronic weight management that have been through rigorous regulatory review. Both require proper clinical assessment and ongoing supervision. Both are prescription-only medicines in the UK. Both work best when combined with genuine lifestyle changes. And both carry a similar commitment from the patient: consistent injection schedule, regular reviews and active engagement with the wider treatment plan.
The choice between them is a clinical and personal one, but choosing either with appropriate support and realistic expectations gives patients in Airdrie a meaningfully better chance of achieving and maintaining their goals than attempting weight management without medical support.
Frequently Asked Questions
Is Saxenda no longer recommended now that Mounjaro is available?
Not exactly. Mounjaro’s trial results are stronger, but Saxenda remains a licensed and clinically appropriate option in certain circumstances. The right choice depends on your individual situation rather than which medication is newer.
Can I switch from Saxenda to Mounjaro?
Yes, this is possible and is a common request. Any switch should be managed by your prescriber, who will advise on timing and whether a washout period is needed before starting the new medication. Once on Mounjaro, practical questions such as whether you can take your injection a day early are also worth understanding from the outset.
Does Mounjaro work faster than Saxenda?
Most patients notice a stronger appetite suppressing effect with Mounjaro over time, but individual responses vary. Both medications build their effects gradually as doses are escalated.
Are the injection pens for Saxenda and Mounjaro similar to use?
Both use pre-filled pen devices for subcutaneous injection, though the pens themselves differ in design. Patients are given instruction on technique for whichever medication they are prescribed.
If Saxenda did not work well for me, will Mounjaro be different?
It may be. The dual mechanism of Mounjaro produces a different pharmacological effect to Saxenda, and some patients who had a limited response to single GLP-1 agonism respond more strongly to dual agonism. A prescriber can assess whether switching is appropriate.
Which medication has fewer side effects?
Both share a similar GLP-1 related side effect profile. Individual experience varies significantly. Mounjaro’s weekly rather than daily schedule means any dose-related side effects are a weekly rather than daily occurrence, which some patients find easier to manage.
Choosing between Saxenda and Mounjaro is a clinical decision that deserves proper discussion. Contact our Airdrie team or book your consultation online to find out which is right for you.
Disclaimer: This blog is intended as a general guide and does not replace personalised medical advice. Both Saxenda and Mounjaro are prescription only medicines. Please visit us or contact us so we can assess which option is most appropriate for your individual circumstances.